This trial is active, not recruiting.

Condition peripheral t-cell lymphoma
Sponsor Spectrum Pharmaceuticals, Inc
Start date February 2010
End date February 2017
Trial size 3000 participants
Trial identifier NCT01110733, COMPLETE Registry


The COMPLETE registry is a prospective, longitudinal, multinational, observational study that will collect data on how patients with peripheral T-cell lymphoma (PTCL) are treated in academic and community practices. The registry will enroll newly-diagnosed patients with PTCL treated with a variety of regimens. The COMPLETE registry is designed to better understand PTCL patient characteristics, treatments, and outcomes to help design and understand future clinical trials.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case-only
Time perspective prospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patient is newly diagnosed with Peripheral T-cell Lymphoma (PTCL): - Aggressive natural killer (NK)-cell leukemia - Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+) - Angioimmunoblastic T-cell lymphoma - Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-) - PTCL, not otherwise specified (NOS) - T/NK-cell lymphoma, nasal type - Enteropathy-type intestinal lymphoma - Hepatosplenic T-cell lymphoma - Subcutaneous panniculitis T-cell lymphoma - Transformed mycosis fungoides (at diagnosis of transformation) - T-cell prolymphocytic leukemia (T-PLL) - Cutaneous gamma/delta (γ/δ) T-cell lymphoma - Cutaneous aggressive CD8+ T-cell lymphoma - Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm) - Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood) - Other T-Cell lymphomas that are not listed in the Exclusion Criteria - Patient gives written informed consent Exclusion Criteria: - Patient has other T- or NK-cell malignancies including: - Precursor T/NK neoplasms - T-cell large granular lymphocytic leukemia - Mycosis fungoides, other than transformed mycosis fungoides - Sézary syndrome - Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis

Additional Information

Official title Prospective, Longitudinal, Multinational Registry of Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
Trial information was received from ClinicalTrials.gov and was last updated in July 2016.
Information provided to ClinicalTrials.gov by Spectrum Pharmaceuticals, Inc.